

## Anti-PD-L1 [10F.9G2] VivopureX 10 mg Ab01419-3.3-VXL

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2b, [Fc Silent™](#), Kappa

**Clone Number:** 10F.9G2

**Alternative Name(s) of Target:** CD274; PDL1; PD L1; Programmed cell death 1 ligand 1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; 10F9G2; 10F 9G2

**UniProt Accession Number of Target Protein:** Q9EP73

**Published Application(s):** Blocking, ELISA, FC, IHC

**Published Species Reactivity:** Mouse

**Immunogen:** This antibody was raised by immunising Lewis rats with murine PD-L1 cDNA and murine PD-L1 CHO transfectants.

**Specificity:** This antibody is specific for murine PD-L1.

**Application Notes:** The specificity of this antibody has been confirmed in ELISA analysis (Eppihimer et al, 2002). This antibody reacts specifically with mPD-L1-transfected cells in flow cytometry, and has been used to assess microvascular endothelial cells PD-L1 expression (Eppihimer et al, 2002). When administered to mice, a radiolabelled version of this antibody has been used to quantify PD-L1 expression in vivo, by measuring antibody accumulation in different tissues (Eppihimer et al, 2002). This antibody has also been used in immunohistochemical analysis of PD-L1 expression in frozen tissue sections of murine brain (Eppihimer et al, 2002) and murine hearts (Rodig et al, 2003). This antibody has been shown to block the binding of PD-L1 to both PD-1 and B7-1 (Paterson et al, 2011). This antibody precipitates diabetes in NOD mice and in adoptive transfer models of CD4+ and CD8+ T cell-driven diabetes, and accelerates diabetes in recipients of T cells from diabetic and prediabetic mice (Paterson et al, 2011).

**Antibody First Published in:** Eppihimer et al. Expression and Regulation of the PD-L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells Microcirculation. 2002 Apr;9(2):133-45. [PMID:11932780](#)

**Note on publication:** Describes the original generation of this antibody, and its use in ELISA, flow cytometry and immunohistochemistry.

## Product Form

**Size:** 10 mg VivopureX products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. These antibodies are chimerized to have an Fc domain matching their target species to reduce immunogenicity and give you the optimal effector function for your experiment. As a result VivopureX products are the ideal choice for in vivo research applications.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions.

**Concentration:**  $\geq 1$ mg (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.